Key result
Current biomarkers for atrial fibrillation do not provide much additional practical value for predicting cardiovascular events beyond recommended scores based only on clinical risk factors.
Why the study?
Atrial fibrillation is increasingly prevalent, and biomarkers have the potential to improve clinical management and reduce health system burden.
Do biomarkers provide additional practical value beyond clinical risk scores for predicting cardiovascular events in patients with atrial fibrillation?
Do biomarkers provide additional practical value beyond clinical risk scores for predicting cardiovascular events in patients with atrial fibrillation?
Current biomarkers for atrial fibrillation do not add significant practical value over standard clinical risk scores for predicting outcomes.
Supports reliance on clinical scores for AF prediction; leaves open whether novel biomarkers will add value.
Introduction Atrial fibrillation is the most common sustained cardiac rhythm disorder, which currently affects 1–2% of the global population. Furthermore, the incidence and prevalence of atrial fibrillation is rising. Biomarkers have the potential to improve clinical management of patients and therefore reduce the burden on health systems in the future.Areas covered A variety of pathways and mechanisms have been associated with atrial fibrillation. This paper provides an overview of a range of blood-based, imaging and genetic biomarkers that are associated with mechanisms and outcomes in atrial fibrillation and their potential use in a clinical setting.Expert commentary Atrial fibrillation is becoming increasingly prevalent. Current biomarkers associated with atrial fibrillation such as those involved in myocardial stress, inflammation, hemostasis and fibrosis do not currently provide much additional practical value beyond recommended scores based only on clinical risk factors.
No takes yet. Share an insight, caveat, or question.
Tidbury et al. (2020) conducted a review in Atrial fibrillation. Biomarkers (blood-based, imaging, and genetic) vs. Clinical risk factor scores was evaluated. Current biomarkers for atrial fibrillation do not provide much additional practical value for predicting cardiovascular events beyond recommended scores based only on clinical risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: